Sweden hopes high-tech biomarker database will help trial recruitment

By Fiona Barry

- Last updated on GMT

The U-CAN programme is based out of Uppsala University, Sweden.
The U-CAN programme is based out of Uppsala University, Sweden.

Related tags: Oncology, Cancer

Sweden is an expert in high-tech trials but stalls in the recruitment phase, says the academic trying to change all that with a database of biomarkers matching patients to studies.

Tobias Sjöblom is Chair of U-CAN, a programme run out of Sweden’s Uppsala University with a grant from the government to create a large registry of standardised data, tumour and blood samples and biomolecules from cancer patients before, during and after therapy.

The data is used for therapeutic and academic purposes but also “to improve the attractiveness of Sweden for clinical trials,​” Sjöblom told Outsourcing-Pharma.com, adding that the platform could change the way the country performs patient recruitment for complicated oncology studies.

Given Sweden’s relatively small population, “it can prevent some of the overenthusiasm [by CROs] – the clinic is typically very positive in the number of patients it can recruit for a trial.​” Trials without enough patients can end up failing.

This will get you a more precise answer as to how many patients are eligible, with very little work. You don’t need to go through records.​”

The scheme was also praised by the head of Stockholm-Uppsala Life Sciences, Ola Bjorkman: “Saving a month in a clinical trial means a month saved in year five, which could be hundreds of millions of euros. It’s really important for pharma companies to get reliable figures on these things.​”


Sweden has a long history of keeping electronic medical records and “quality registries​” of patient details. But typically it takes 12 months for forms on a cancer patient’s disease and treatment to be filled in and registered.

As a result, the lag of one year means the patient details are not helpful to CROs looking to recruit for oncology trials.

They want real-time information to decide whether to do clinical trials. We also need much more detailed information than what is in the quality registries,​” said Sjöblom.

The U-CAN databases collect biomolecules, tumour and blood samples, radiological images and other patient data, all in a standardised format. The programme has been running since 2010 at Uppsala and Umeå University Hospitals and has begun in the surrounding counties.

Almost 7,000 cancer sufferers are now in the system. The project aims to cover 30% of Sweden’s oncology patients.

U-CAN offers pharma companies research collaborations using longitudinal information and biobanked material.

It is currently working on a Phase I trial for personalised breast cancer vaccines with German firm Biontec, “where the personalisation is based on the inexpression and mutation profile of the patient tumour – it’s one of the more sophisticated early clinical trials.​”

U-CAN is also collaborating with Swedish firm Olink, which develops antibody-based assays for plasma, and with a company looking for patients for circulating tumour DNA (ctDNA) research.

Related news

Related products

show more

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Planning Your Preclinical Assessment

Planning Your Preclinical Assessment

Altasciences | 17-Jan-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 17-Jan-2022 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Related suppliers

Follow us


View more